![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 23, 20131-20134, June 7, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, February 20, 2002, and in revised form, April 16, 2002
Dietary cholesterol has been shown to have a
stimulatory effect on the murine cholesterol 7 Bile acids represent the terminal end products of cholesterol
catabolism. Bile acid synthesis takes place exclusively in the liver
(1, 2). The pathway responsible for the synthesis of the bulk of bile
acids in the enterohepatic circulation is controlled by a microsomal
enzyme known as cholesterol 7 Much of what is known about the regulation of cyp7a gene expression has
come from studies involving animal models. It has been known for a long
time that cyp7a gene expression in rodents is repressed by bile acids
and stimulated by cholesterol. The inhibition of cyp7a gene expression
by bile acids is accomplished via an indirect mechanism that involves a
nuclear factor that interferes with gene transcription (3-5). The
stimulation of cyp7a gene expression by cholesterol is mediated through
liver X receptor (LXR Very little is known regarding the regulation of the gene encoding the
human cyp7a (CYP7A1), particularly under non-pathological conditions. In this report, we describe the creation of a new mouse
model that uniquely expresses the human CYP7A1 gene in the liver. We used this model to evaluate the response of the human CYP7A1 gene to regulation by dietary cholesterol in the
intact animal, in an effort to gain insight into the mechanisms that regulate human CYP7A1 gene expression in
vivo.
Mice--
Transgenic mice were produced by injecting an entire
bacterial artificial chromosome (~125 kb) containing the human
CYP7A1 gene into C57BL/6×CBA zygotes using standard
procedures. The injected CYP7A1 gene was flanked by >17 kb
and >6 kb of sequence at the 5' and 3' regions, respectively.
Incorporation of the CYP7A1 gene into the genomes of mice
born from injected eggs was assessed by screening of tail DNA by PCR
analysis using CYP7A1 gene-specific primers (sense,
5'-TCTGAACTTGATCACCGTCTCTCTG-3'; antisense,
5'-GTCGACCAAATCTAGGCCAAAATCT-3') and confirmed by DNA blot analysis.
The murine Mos gene (9) served as the internal control
target in the PCR analyses (sense, 5'-TCAGATTTGTGCATACACAGTGACT-3';
antisense, 5'-ACTCAACTTTTATTCCCGAAAAATGTTTCA-3') of mouse genomic DNA.
Transgenic mice were crossed with C57BL6/J mice, and the resulting F1
generation was analyzed for transgene inheritance and expression. The
human CYP7A1 gene was detected by DNA blotting using the rat
cyp7a cDNA as a probe. The human cyp7a mRNA was detected in
total liver RNA (see below for details), and the human cyp7a enzyme was
detected by immunoblotting using rabbit antiserum directed against the
last five carboxyl-terminal amino acid residues of human cyp7a. The
CYP7A1 transgenic mouse line in which the human cyp7a
mRNA and enzyme could be detected unequivocally was expanded. A
male transgenic mouse from the F2 generation was used to breed the
CYP7A1 transgene into female Cyp7a1 Detection of mRNA and Quantitation of Abundance--
RNA was
purified from tissues according to a standard procedure (10).
Complementary DNA was synthesized from 10 µg of total RNA with
Superscript II reverse transcriptase (Invitrogen Canada, Inc.,
Burlington, Ontario, Canada) following the manufacturer's suggested
protocol. The human cyp7a mRNA was detected by RT-PCR using
species-specific and intron-spanning primers (sense,
5'-AGAAGGCAAACGGGTGAACC-3'; antisense, 5'-GGGTCAATGCTTCTGTGCCC) and by
high stringency RNA blotting using the 3'-untranslated region of the
human cyp7a cDNA as a probe. The cyclophilin mRNA served as the
internal control target in the PCR analysis using intron-spanning
primers (sense, 5'-TCCAAAGACAGCAGAAAACTTTCG-3'; antisense,
5'-TCTTCTTGCTGGTCTTGCCATTCC-3'). Murine AbcA1 mRNA was
detected by RT-PCR using intron spanning primers (sense,
5'-GACGATATCTCGATTCATGG-3'; antisense, 5'-CACGTTGTCAATGTCCATCC-3'). The
relative abundance of mRNA species of interest was determined by quantitative real-time PCR. Polymerase chain reactions were done
with REDTaq DNA polymerase (Sigma-Aldrich) and intron-spanning, gene-specific oligonucleotides as described above in the presence of
1× SYBR Green I (supplied as a 10,000× stock; Sigma-Aldrich). The
annealing temperature of each oligonucleotide pair was preoptimized using a T- Gradient thermal cycler (Whatman Biometra,
Göttingen, Germany) to ensure the synthesis of only the expected
amplicon. Quantitative synthesis of the amplicons was monitored by
green fluorescence using a LightCycler (Roche Diagnostics Canada,
Laval, Quebec, Canada). The range of cycle numbers in which
amplification remained linear was also predetermined. The mass of
amplicons synthesized was quantitated using the LightCycler software
package (Roche Diagnostics Canada). Cyclophilin mRNA was used as
the internal standard, and its abundance varied less than 10% among
all samples analyzed. All reactions were confirmed visually by agarose
gel electrophoresis.
Cell Culture and Transient Transfections--
Culture conditions
for McArdle RH7777 cells, the transfection procedure, and the
structures of the human and murine cyp7a promoter-chloramphenicol
acetyltransferase (CAT) gene chimeras (hCYP7A1.CAT and mCyp7a1.CAT,
respectively) were described previously (11). Cultures (60-mm dishes,
60% confluent) were transfected with a mixture of plasmids containing
a cyp7a-CAT gene chimera (1 µg), expression plasmids encoding LXR Eletrophoretic Mobility Shift Assays--
Recombinant LXR Assay for cyp7a Enzyme Activity--
Conditions for the assay of
cyp7a enzyme activity were described previously (12).
We obtained nine mice from injected fertilized eggs that had
incorporated the transgene into their genomes, and five of these transmitted the transgene to their offspring (see Supplemental Table I
for details). The human cyp7a mRNA was detectable in only three of
the five lines. One of these lines produced very small litters and was
not bred further. The human cyp7a mRNA and enzyme (Fig.
1, A and B,
respectively) were unequivocally detectable in only one (line M49) of
the two remaining lines, and this was selected to establish a colony.
The F3 generation was produced by crossing two hemizygous transgenic
mice.
The human CYP7A1 transgene was subsequently transferred to
the Cyp7a1
ACCELERATED PUBLICATION
Dietary Cholesterol Fails to Stimulate the Human Cholesterol
7
-Hydroxylase Gene (CYP7A1) in Transgenic
Mice*,
§,
,
¶,
, and
Department of Biochemistry and Canadian
Institutes of Health Research Group in Molecular and Cell Biology of
Lipids, University of Alberta, Edmonton, Alberta T6G 2S2, Canada and
the
Laboratory of Biochemical Genetics and Metabolism,
Rockefeller University, New York, New York 10021-6399
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-hydroxylase gene
(Cyp7a1), but its effect on human cholesterol
7
-hydroxylase gene (CYP7A1) expression in
vivo is not known. A transgenic mouse strain harboring the human
CYP7A1 gene and homozygous for the disrupted murine
Cyp7a1 gene was created. Cholesterol feeding increased the
expression of the endogenous modified Cyp7a1 allele but
failed to stimulate the human CYP7A1 transgene. In
transfected hepatoma cells, 25-hydroxycholesterol increased murine
Cyp7a1 gene promoter activity, whereas the human CYP7A1 gene promoter was unresponsive. Electrophoretic
mobility shift assays demonstrated the interaction of the liver X
receptor
(LXR
): retinoid X receptor (RXR) heterodimer, a
transcription factor complex that is activated by oxysterols, with the
murine Cyp7a1 gene promoter, whereas no binding to the
human CYP7A1 gene promoter was detected. The results
demonstrate that the human CYP7A1 gene is not stimulated by
dietary cholesterol in the intact animal, and this is attributable to
the inability of the CYP7A1 gene promoter to interact with
LXR
:RXR.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-hydroxylase (cyp7a).1 The activity of
cyp7a is regulated by a variety of nutritional and hormonal factors
involving both feedback and feedforward mechanisms. The regulatory
control appears to be exerted mainly at the level of gene
transcription, since cyp7a activity is highly correlated with cyp7a
mRNA abundance.
), an oxysterol-activated nuclear receptor that binds to the cyp7a gene promoter as a heterodimer with another nuclear
receptor known as retinoid X receptor (RXR) (6-8).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
/
mice obtained from The Jackson
Laboratory (Bar Harbor, ME). The F1 progeny of this cross were
interbred to produce F2 CYP7A1 transgenic mice that were
also homozygous for the disrupted Cyp7a1 allele. Zygosity to
the mutant Cyp7a1 allele was evaluated by PCR analysis using
a primer pair (IMR013, 5'-CTTGGGTGGAGAGGCTATTC-3'; IMR014, 5'-AGGTGAGATGACAGGAGATC-3') specific for the neomycin
phosphotransferase gene (neor) that is embedded in
the disrupted Cyp7a1 allele and a primer pair (IMR594,
5'-GATGTATGCCTTCTGCTACCG-3'; IMR595, 5'-TCACAAGGTGCGTCTTAGCC-3') specific for a segment of the wild type Cyp7a1 gene that is
absent in the mutant Cyp7a1 allele. The IMR primers
described above are documented in the Induced Mutation Resource at the
Jackson Laboratory (Bar Harbor, ME). One male and one female mouse from
the F3 generation, bearing the desired genotype, were crossed to
generate the line used in this study. The mice (both sexes) were fed a
standard chow diet (Purina Rodent Chow 5001) or, where indicated, the
chow diet supplemented with 1% (w/w) cholesterol for 14 days. The use of animals in this study was approved by the University of Alberta Health Sciences Animal Welfare and Policy Committee.
(0.5 µg, pCMX-LXR
), RXR
(0.5 µg, pSG5-RXR
), and
-galactosidase (pCH110; 5 µg). Sonicated salmon sperm DNA was
added to the mixture to give a mass of 10 µg of DNA added per dish.
The 25-hydroxycholesterol (dissolved in ethanol; Sigma-Aldrich) was
used as the activator of LXR
(at 5 µM final
concentration). Controls received an equivalent amount of ethanol. The
-galactosidase activity encoded by pCH110 was used to normalize
transfection efficiency.
and
RXR were produced in Escherichia coli and partially
purified. The cyp7a Site I sequences (human, 5'-TTGTCAACCAAGCTCA-3'; murine, 5'-TGGTCACCCAAGTTCA-3') were described previously (11). Unlabeled double-stranded oligonucleotide probes contained overhangs (5'-AATT-3'), which allowed radiolabeling with 32P-labeled
deoxyribonucleotides by fill-in reaction catalyzed by the Klenow
fragment of E. coli DNA polymerase I. The probe and recombinant receptors (100 ng) were incubated with 4 µg of
poly(dI:dC), 4 µg of bovine serum albumin, 1 µg of sonicated salmon
sperm DNA in binding buffer (40 mM Tris-HCl, pH 7.9, 4 mM MgCl2, 100 mM NaCl, 2 mM EDTA, 20% glycerol, 0.2% Nonidet P-40, 2 mM dithiothreitol) for 20 min at room temperature in
a total volume of 40 µl. In competition binding experiments, a
double-stranded oligonucleotide bearing an idealized LXR binding site
(5'-AGTTCACTCAAGTTCA-3') was added to the binding reactions prior to
the addition of radiolabeled Site I probes. DNA-protein complexes were
separated from unbound probe by electrophoresis on a 4% polyacrylamide
gel and visualized by phosphorimaging using a Bio-Rad Molecular Imager
FX Pro Plus MultiImager System.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (31K):
[in a new window]
Fig. 1.
Characterization of human CYP7A1
gene expression in the liver of transgenic mice.
A shows the detection of a ~2900-nucleotide transcript
(arrow) in total liver RNA (30 µg per lane) by RNA
blotting using a cDNA fragment corresponding to the 3'-untranslated
region of the human cyp7a mRNA. The positions of 28 and 18 S
ribosomal RNA are indicated on the left. B shows
a ~57.7-kDa protein (arrow) in hepatic microsomal proteins
(20 µg of total microsomal proteins per lane) that is immunoreactive
to an antiserum against the last five carboxyl-terminal amino acid
residues of the human cyp7a enzyme. The positions of molecular
mass markers are indicated on the left.
non-Tg, non-transgenic; Tg, transgenic.
/
background by crossing a
transgenic male mouse from the F3 generation with female
Cyp7a1
/
mice. The progeny of this cross were
heterozygous for the disrupted Cyp7a1 allele, and all
contained the human CYP7A1 transgene. As shown in Fig.
2A, both the human
CYP7A1 gene and the disrupted murine Cyp7a1 gene
hybridization patterns (left and right lanes, respectively) are evident in the progeny of this cross (middle lane). A male and female mouse from this generation were mated to
reestablish homozygosity to the disrupted Cyp7a1 allele.
From the progeny of this cross, one male and one female mouse, which carried the desired genotype, were selected to establish the second colony. Fig. 2B shows the genotype analysis of
Cyp7a1
/
mice carrying the human
CYP7A1 transgene (hereafter referred to as hCYP7A1 mice). As
can be seen (Fig. 2B, lane 5), the
human CYP7A1 transgene is clearly detectable, and the wild
type Cyp7a1 allele has been replaced with the disrupted
Cyp7a1 allele. Expression of the human CYP7A1
transgene in Cyp7a1
/
mice reversed postnatal
lethality observed in Cyp7a1
/
mice (13). The
hCYP7A1 pups were overtly indistinguishable from wild type pups and
survived to weaning without supplementing the standard diet of nursing
mothers with bile acids or fat-soluble vitamins.

View larger version (50K):
[in a new window]
Fig. 2.
Characterization of CYP7A1
transgenic/Cyp7a1 gene-disrupted hybrid
mice. A shows the DNA blot hybridization patterns of
the human CYP7A1 gene (CYP7A1 BAC) contained in
the bacterial artificial chromosome used to develop transgenic mice,
tail DNA of a mouse
(Tg(CYP7A1)Cyp7a1
/
) from the F2
generation, and tail DNA of a mouse homozygous for the disrupted
Cyp7a1 allele (Cyp7a1
/
).
B shows the unambiguous detection by PCR of the human
CYP7A1 transgene, the wild type murine Cyp7a1
gene, the neomycin phosphotransferase gene (neor)
embedded in the disrupted Cyp7a1 gene and the murine
Mos gene (positive control target) in the various mice used
in the experiments: wild type, Cyp7a1+/+; murine
cyp7a-deficient, Cyp7a1
/
; human
CYP7A1 transgenic,
Tg(CYP7A1)Cyp7a1+/+; and murine
cyp7a-deficient human CYP7A1 transgenic,
Tg(CYP7A1)Cyp7a1
/
. The lane
labeled Blank represents reactions without template DNA.
C shows the distribution of the human cyp7a mRNA
detected by RT-PCR as described under "Experimental Procedures."
The cyclophilin mRNA was used as the internal control target. The
ethidium bromide-stained gels (B and C) are shown
as a negative image.
Liver expression of the CYP7A1 transgene in mice possessing the wild type Cyp7a1 gene was reported earlier (14), but the tissue distribution was not determined. Thus, we surveyed the distribution of CYP7A1 transgene expression in hCYP7A1 mice. As shown in Fig. 2C, the human cyp7a mRNA is detectable only in the liver. This result demonstrates that the liver-specific expression of the human CYP7A1 gene is faithfully reproduced in the murine species.
The stimulation of the murine Cyp7a1 gene expression by
dietary cholesterol is well documented (8, 15, 16). Thus, we compared
the expression of the CYP7A1 transgene in mice fed the standard chow diet or the chow diet supplemented with 1% cholesterol for 14 days. Although the Cyp7a1
/
mice do
not synthesize the cyp7a enzyme, the disrupted murine Cyp7a1 allele continues to be transcribed producing an
mRNA species that is a composed of cyp7a and
neor sequences (13). The changes in the abundance of
the chimeric murine cyp7a/neor mRNA in response to
cholesterol feeding were also monitored. As shown in Fig.
3A, the murine
cyp7a/neor mRNA was increased by 40%
(p < 0.0005) in hCYP7A1 mice. This rise in cyp7a/
neor is in agreement with the expected response of
the murine Cyp7a1 gene to dietary cholesterol. In contrast,
the abundance of the human cyp7a mRNA was decreased by 56%
(p < 0.005). The Abca1 gene is expressed in
the liver (17) and is known to be stimulated by oxysterols (18). A
7.8-fold rise (p < 0.006) in AbcA1 mRNA abundance
in total liver RNA of cholesterol-fed versus chow-fed hCYP7A1 mice was evident (Fig. 3B). Although it is not clear
which hepatic cell type expresses the Abca1 gene, the result
is nevertheless consistent with the exposure of the liver of
cholesterol-fed mice to the dietary cholesterol. The hepatic cyp7a
enzyme activity of chow-fed hCYP7A1 mice is lower than that of chow-fed
wild type mice, which may be due to the lower level of human
CYP7A1 transgene expression relative to that of the murine
Cyp7a1 gene in wild type mice. The cholesterol diet
decreased hepatic cyp7a enzyme activity by 55% (p < 0.02) in hCYP7A1 mice, concomitant with the fall of human cyp7a
mRNA abundance (Fig. 3C). These results clearly illustrate the failure of dietary cholesterol to stimulate human CYP7A1 transgene expression in mice. The apparent repression
of human CYP7A1 gene expression by dietary cholesterol was
unexpected, and the basis for this is not clear. It is evident that, in
intact animals, the human CYP7A1 and murine
Cyp7a1 genes respond differently to dietary cholesterol.
|
The findings obtained in vivo were verified in hepatoma
cells. It is known that oxysterols regulate the activity of responsive promoters by activating nuclear receptors known as the LXR, which are
bound to response elements as heterodimers with RXRs (6). The murine
Cyp7a1 gene promoter contains an LXR:RXR binding site (termed Site I; Fig. 4A) (11),
which is similar in sequence to the rat Cyp7a1 LXR binding
site (19). In addition, the inactivation of the murine gene encoding
the LXR
isoform results in the resistance of the Cyp7a1
gene to stimulation by dietary cholesterol (8). Thus, we compared the
response of the human and murine gene promoters to oxysterol-activated
LXR
:RXR. Fig. 4B shows a 30-fold increase (p < 0.001) in reporter activity from the murine
mCyp7a1.CAT gene chimera when LXR
was activated by
25-hydroxycholesterol, whereas no response was evident from the human
hCYP7A1.CAT gene chimera. A similar finding for the human
CYP7A1 gene promoter was also documented in HepG2 cells
(19). Analysis of recombinant LXR
:RXR interaction with human and
murine Site I by electrophoretic mobility shift assay demonstrated avid
binding of the heterodimer to the murine Site I, but no detectable
binding to the human Site I was found (Fig. 4C). Moreover,
the binding of LXR
:RXR to the murine Site I could be efficiently
competed by an idealized LXR
:RXR binding site, illustrating the
specificity of the interaction. These results demonstrate that the
human and murine Site I sequence dictates the interaction of the
LXR
:RXR with the human and murine cyp7a gene promoter and
subsequently their response to cholesterol. We surveyed the sequence of
the Site I in a small cohort of unrelated individuals from different
ethnic backgrounds. This analysis revealed that the human Site I
sequence was invariant (Supplemental Fig. 1), implying a similar
general response of the human CYP7A1 gene to transcriptional
control at this regulatory site.
|
In summary, we have described the creation of a mouse strain that
uniquely expresses the human cyp7a enzyme in the liver. This model has
permitted us to evaluate the response of the human CYP7A1
gene to dietary cholesterol in the intact animal, under the same
conditions normally used to study murine Cyp7a1 gene expression but without interference from the functional consequences of
the endogenous Cyp7a1 gene. The results obtained demonstrate that the human CYP7A1 gene is not stimulated by dietary
cholesterol in vivo. Previously we showed that the murine
Cyp7A1 gene promoter is induced by fats more robustly
compared with the human CYP7A1 gene promoter in hepatoma
cells (11). We have also found that the activity of the human
CYP7A1 gene promoter is repressed by thyroid hormone (20),
contrary to the response described for murine and rat Cyp7a1
gene promoters (21-24). These findings may be illustrating a
fundamental difference in the way the human CYP7A1 and
murine Cyp7a1 genes are normally regulated in
vivo.
| |
ACKNOWLEDGEMENT |
|---|
We gratefully acknowledge the excellent technical help provided by Jody Seewalt.
| |
FOOTNOTES |
|---|
* This work was supported by Grant MOP-14812 from the Canadian Institutes of Health Research (to L. B. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at
http://www.jbc.org) contains Supplemental Fig. 1 and Supplemental Table I.
§ Senior Scholar of the Alberta Heritage Foundation for Medical Research. To whom correspondence should be addressed: 328 Heritage Medical Research Center, University of Alberta, Edmonton, AB T6G 2S2, Canada. Tel.: 780-492-5251; Fax: 780-492-3383; E-mail: luis.agellon@ualberta.ca.
¶ Present address: Dept. of Biochemistry, Memorial University of Newfoundland, St. John's, NF A1B 3X9, Canada.
Published, JBC Papers in Press, April 19, 2002 DOI 10.1074/jbc.C200105200
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
cyp7a, cholesterol 7
-hydroxylase;
LXR
, liver X receptor
;
RXR, retinoid X receptor;
RT, reverse transcriptase;
CAT, chloramphenicol
acetyltransferase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Russell, D. W., and Setchell, K. D. R. (1992) Biochemistry 31, 4737-4749[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Agellon, L. B., and Torchia, E. C. (2000) Biochim. Biophys. Acta 1486, 198-209[Medline] [Order article via Infotrieve] |
| 3. | Lu, T. T., Makishima, M., Repa, J. J., Schoonjans, K., Kerr, T. A., Auwerx, J., and Mangelsdorf, D. J. (2000) Mol. Cell 6, 507-515[CrossRef][Medline] [Order article via Infotrieve] |
| 4. | Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., Maloney, P. R., Willson, T. M., and Kliewer, S. A. (2000) Mol. Cell 6, 517-526[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Gupta, S.,
Stravitz, R. T.,
Dent, P.,
and Hylemon, P. B.
(2001)
J. Biol. Chem.
276,
15816-15822 |
| 6. | Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. J. (1996) Nature 383, 728-731[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Lehmann, J. M.,
Kliewer, S. A.,
Moore, L. B.,
Smith-Oliver, T. A.,
Oliver, B. B., Su, J.-L.,
Sundseth, S. S.,
Winegar, D. A.,
Blanchard, D. E.,
Spencer, T. A.,
and Willson, D. E.
(1997)
J. Biol. Chem.
272,
3137-3140 |
| 8. | Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E., and Mangelsdorf, D. J. (1998) Cell 93, 693-704[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Wood, T. G., McGeady, M. L., Baroudy, B. M., Blair, D. G., and Vande Woude, G. F. (1984) Proc. Natl. Acad. Sci. U. S. A. 24, 7817-7821 |
| 10. | Chomczynski, P., and Sacchi, N. (1987) Anal. Biochem. 162, 156-158[Medline] [Order article via Infotrieve] |
| 11. |
Cheema, S. K.,
and Agellon, L. B.
(2000)
J. Biol. Chem.
275,
12530-12536 |
| 12. | Agellon, L. B. (1997) Biochem. Cell Biol. 75, 255-262[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Ishibashi, S.,
Schwarz, M.,
Frykman, P. K.,
Herz, J.,
and Russell, D. W.
(1996)
J. Biol. Chem.
271,
18017-18023 |
| 14. | Goodart, S. A., Huynh, C., Chen, W., Cooper, A. D., and Levy-Wilson, B. (1999) Biochem. Biophys. Res. Commun. 266, 454-459[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Torchia, E. C., Cheema, S. K., and Agellon, L. B. (1996) Biochem. Biophys. Res. Commun. 255, 128-133 |
| 16. |
Schwarz, M.,
Russell, D. W.,
Dietschy, J. M.,
and Turley, S. D.
(2001)
J. Lipid Res.
42,
1594-1603 |
| 17. | Qiu, Y., Cavelier, L., Chiu, S., Yang, X., Rubin, E., and Cheng, J. F. (2001) Genomics 73, 66-76[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Repa, J. J.,
Turley, S. D.,
Lobaccaro, J. A.,
Medina, J., Li, L.,
Lustig, K.,
Shan, B.,
Heyman, R. A.,
Dietschy, J. M.,
and Mangelsdorf, D. J.
(2000)
Science
289,
1524-1529 |
| 19. | Chiang, J. Y., Kimmel, R., and Stroup, D. (2001) Gene (Amst.) 262, 257-265[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Drover, V. A.,
Wong, N. C.,
and Agellon, L. B.
(2002)
Mol. Endocrinol.
16,
14-23 |
| 21. | Ness, G. C., Pendleton, L. C., Li, Y. C., and Chiang, J. Y. L. (1990) Biochem. Biophys. Res. Commun. 172, 1150-1156[CrossRef][Medline] [Order article via Infotrieve] |
| 22. |
Hylemon, P. B.,
Gurley, E. C.,
Stravitz, R. T.,
Litz, J. S.,
Pandak, W. M.,
Chiang, J. Y.,
and Vlahcevic, Z. R.
(1992)
J. Biol. Chem.
267,
16866-16871 |
| 23. | Ness, G. C., Pendelton, L. C., and Zhao, Z. (1994) Biochim. Biophys. Acta 1214, 229-233[Medline] [Order article via Infotrieve] |
| 24. |
Gullberg, H.,
Rudling, M.,
Forrest, D.,
Angelin, B.,
and Vennstrom, B.
(2000)
Mol. Endocrinol.
14,
1739-1749 |
This article has been cited by other articles:
![]() |
Y.-K. Lee, D. R. Schmidt, C. L. Cummins, M. Choi, L. Peng, Y. Zhang, B. Goodwin, R. E. Hammer, D. J. Mangelsdorf, and S. A. Kliewer Liver Receptor Homolog-1 Regulates Bile Acid Homeostasis but Is Not Essential for Feedback Regulation of Bile Acid Synthesis Mol. Endocrinol., June 1, 2008; 22(6): 1345 - 1356. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Stayrook, P. M. Rogers, R. S. Savkur, Y. Wang, C. Su, G. Varga, X. Bu, T. Wei, S. Nagpal, X. S. Liu, et al. Regulation of Human 3{alpha}-Hydroxysteroid Dehydrogenase (AKR1C4) Expression by the Liver X Receptor {alpha} Mol. Pharmacol., February 1, 2008; 73(2): 607 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gilham, E. D. Labonte, J. C. Rojas, R. J. Jandacek, P. N. Howles, and D. Y. Hui Carboxyl Ester Lipase Deficiency Exacerbates Dietary Lipid Absorption Abnormalities and Resistance to Diet-induced Obesity in Pancreatic Triglyceride Lipase Knockout Mice J. Biol. Chem., August 24, 2007; 282(34): 24642 - 24649. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kanayama, M. Arito, K. So, S. Hachimura, J. Inoue, and R. Sato Interaction between Sterol Regulatory Element-binding Proteins and Liver Receptor Homolog-1 Reciprocally Suppresses Their Transcriptional Activities J. Biol. Chem., April 6, 2007; 282(14): 10290 - 10298. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. P. Ratliff, A. Gutierrez, and R. A. Davis Transgenic expression of CYP7A1 in LDL receptor-deficient mice blocks diet-induced hypercholesterolemia J. Lipid Res., July 1, 2006; 47(7): 1513 - 1520. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hashimoto, R. N. Cohen, M. Yamada, K. R. Markan, T. Monden, T. Satoh, M. Mori, and F. E. Wondisford Cross-talk between Thyroid Hormone Receptor and Liver X Receptor Regulatory Pathways Is Revealed in a Thyroid Hormone Resistance Mouse Model J. Biol. Chem., January 6, 2006; 281(1): 295 - 302. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Bastie, Z. Nahle, T. McLoughlin, K. Esser, W. Zhang, T. Unterman, and N. A. Abumrad FoxO1 Stimulates Fatty Acid Uptake and Oxidation in Muscle Cells through CD36-dependent and -independent Mechanisms J. Biol. Chem., April 8, 2005; 280(14): 14222 - 14229. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. V. Boekschoten, M. K. Hofman, R. Buytenhek, E. G. Schouten, H. M. G. Princen, and M. B. Katan Coffee Oil Consumption Increases Plasma Levels of 7{alpha}-Hydroxy-4-cholesten-3-one in Humans J. Nutr., April 1, 2005; 135(4): 785 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Honda, G. Salen, Y. Matsuzaki, A. K. Batta, G. Xu, T. Hirayama, G. S. Tint, M. Doy, and S. Shefer Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis J. Lipid Res., February 1, 2005; 46(2): 287 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gilham, M. Alam, W. Gao, D. E. Vance, and R. Lehner Triacylglycerol Hydrolase Is Localized to the Endoplasmic Reticulum by an Unusual Retrieval Sequence where It Participates in VLDL Assembly without Utilizing VLDL Lipids as Substrates Mol. Biol. Cell, February 1, 2005; 16(2): 984 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Bastie, T. Hajri, V. A. Drover, P. A. Grimaldi, and N. A. Abumrad CD36 in Myocytes Channels Fatty Acids to a Lipase-Accessible Triglyceride Pool That Is Related to Cell Lipid and Insulin Responsiveness Diabetes, September 1, 2004; 53(9): 2209 - 2216. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Riddick, C. Lee, A. Bhathena, Y. E. Timsit, P.-Y. Cheng, E. T. Morgan, R. A. Prough, S. L. Ripp, K. K. M. Miller, A. Jahan, et al. TRANSCRIPTIONAL SUPPRESSION OF CYTOCHROME P450 GENES BY ENDOGENOUS AND EXOGENOUS CHEMICALS Drug Metab. Dispos., April 1, 2004; 32(4): 367 - 375. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Tiemann, Z. Han, R. Soccio, J. Bollineni, S. Shefer, E. Sehayek, and J. L. Breslow Cholesterol feeding of mice expressing cholesterol 7{alpha}-hydroxylase increases bile acid pool size despite decreased enzyme activity PNAS, February 17, 2004; 101(7): 1846 - 1851. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. F. Gbaguidi and L. B. Agellon The inhibition of the human cholesterol 7{alpha}-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver x receptor {alpha} and peroxisome proliferator-activated receptor {alpha} heterodimer Nucleic Acids Res., February 11, 2004; 32(3): 1113 - 1121. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. B. Drover and L. B. Agellon Regulation of the Human Cholesterol 7{alpha}-Hydroxylase Gene (CYP7A1) by Thyroid Hormone in Transgenic Mice Endocrinology, February 1, 2004; 145(2): 574 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ricote, A. F. Valledor, and C. K. Glass Decoding Transcriptional Programs Regulated by PPARs and LXRs in the Macrophage: Effects on Lipid Homeostasis, Inflammation, and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 230 - 239. [Abstract] [Full Text] |
||||
![]() |
M. Fuchs Bile Acid Regulation of Hepatic Physiology: III. Regulation of bile acid synthesis: past progress and future challenges Am J Physiol Gastrointest Liver Physiol, April 1, 2003; 284(4): G551 - G557. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. L. Chiang Bile Acid Regulation of Hepatic Physiology: III. Bile acids and nuclear receptors Am J Physiol Gastrointest Liver Physiol, March 1, 2003; 284(3): G349 - G356. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Goodwin, M. A. Watson, H. Kim, J. Miao, J. K. Kemper, and S. A. Kliewer Differential Regulation of Rat and Human CYP7A1 by the Nuclear Oxysterol Receptor Liver X Receptor-{alpha} Mol. Endocrinol., March 1, 2003; 17(3): 386 - 394. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Chen, B. Levy-Wilson, S. Goodart, and A. D. Cooper Mice Expressing the Human CYP7A1 Gene in the Mouse CYP7A1 Knock-out Background Lack Induction of CYP7A1 Expression by Cholesterol Feeding and Have Increased Hypercholesterolemia When Fed a High Fat Diet J. Biol. Chem., November 1, 2002; 277(45): 42588 - 42595. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakahara, H. Fujii, P. R. Maloney, M. Shimizu, and R. Sato Bile Acids Enhance Low Density Lipoprotein Receptor Gene Expression via a MAPK Cascade-mediated Stabilization of mRNA J. Biol. Chem., September 27, 2002; 277(40): 37229 - 37234. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||